Effect of perindopril on Fas/Apo-1 in patients with congestive heart failure
Wang Xiao · Di-Si Junyi Daxue xuebao · 2003
AIM: To observe the effect of perindopril on the cardiac function and serum level of Fas/Apo 1 in patients with congestive heart failure (CHF). METHODS: Level of serum Fas/Apo 1 was determined by enzyme linked immunosorbent assay (ELISA) in 84 CHF cases (42 treated with perindopril and 42 with conventional method) and 30 healthy cases as control. RESULTS: ① The level of Fas/Apo 1 in the 84 CHF cases was much higher than that in the control cases [(0.20±0.07) μg·L -1 vs (0.10±0.04) μg·L -1 , P 0.01] and increased significantly with the aggravation of cardiac dysfunction. ② Before treatment, there was no significant difference in serum level of Fas/Apo 1 between perindopril group and conventional group[(0.20±0.07) μg·L -1 vs (0.21±0.07) μg·L -1 ], but after treatment, the Fas/Apo 1 level in the perindopril group was significantly lower ( P 0.01) than that in conventional group [(0.12±0.04) μg·L -1 vs (0.15±0.05) μg·L -1 , P 0.01]. CONCLUSION: Level of circulating Fas/Apo 1 can be used to determine the cardiac dysfunction degree and perindopril may play an important role in protecting cardiac function by inhibiting the myocardium apoptosis process in patients with CHF.